Ervebo FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 29, 2020.
FDA Approved: Yes (First approved December 19, 2019)
Brand name: Ervebo
Generic name: ebola zaire vaccine, live
Previous name: rVSV∆G-ZEBOV-GP, live attenuated
Dosage form: Injection
Previous Name: V920
Treatment for: Prevention of Ebola Zaire Disease
Ervebo (ebola zaire vaccine, live) is a vaccine indicated for the prevention of disease caused by Zaire ebolavirus in individuals 18 years of age and older.
Development timeline for Ervebo
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.